Car t nomenclature and positioning-2
•
1 like•500 views
CAR-T Nomenclature and Positioning
Recommended
Recommended
More Related Content
What's hot
What's hot (15)
Similar to Car t nomenclature and positioning-2
Similar to Car t nomenclature and positioning-2 (20)
Recently uploaded
Recently uploaded (20)
Car t nomenclature and positioning-2
- 1. CAR-T: Market Perspectives April 15, 2015 Brand Acumen The Global Leader in Pharmaceutical Name Development
- 2. CAR-T: Market Positioning 2 The purpose of this presentation is to examine the CAR-T market landscape with an eye on brand positioning, market messaging and current external perceptions. The contents include a high level overview of the nomenclature and nascent brand architecture of the primary companies, a review of the evolving CAR-T lexicon, and the results of a CAR-T specific Brand Equity Perception Study conducted in March, 2015. Differentiation Dimensions Overview: The CAR-T Nomenclature and Nascent Brand Architecture Brand Acumen’s CAR-T Brand Equity Perception Study March, 2015 A Review of the Evolving CAR-T Lexicon
- 4. CAR-T anewlexicon chimeric antigen receptor therapy
- 5. SurveyDesign 5 To initiate the CAR-T Brand Equity Study we surveyed five segments of Key Innovation Leaders (KILs). • Bio Industry Writers (8) • Venture Capitalists (7) • Oncologists (35) • CAR-T Specific Researchers (21) • Market Makers/Analysts (12) CAR-TBrandEquityPerceptionStudy Brand Acumen’s CAR-T Brand Equity survey methodology brings together market, brand, competitive, and technological attribute perceptions. A corporate brand’s performance can be assessed allowing for a roadmap for improvement to be identified in micro-niche biotech ecosystems. samplesize/ numberofrespondents Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
- 6. chimeric antigen receptor therapy CAR-T: The Main Players A Review of Company Nomenclature and Results of the Brand Acumen CAR-T Brand Equity Perception Study
- 7. 7 CAR-T nomenclature @NascentCAR-TNomenclature tisagenlecleucel-T Alternative Names: • Anti-CD19-CAR retroviral vector-transduced autologous T cells - University of Pennsylvania • Anti-CD19-CAR transduced T cells - Novartis/University of Pennsylvania • CART-019; CART-19; CART-19 cells • Chimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/Novartis • CTL 019 • LG-740 Most Recent Events 26 Feb 2015 Phase-II clinical trials in Diffuse large B cell lymphoma in USA (IV) (Novartis, pipeline, February 2015) 08 Dec 2014 Efficacy data from a pediatric study in Acute lymphoblastic leukemia presented at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2014) 15 Oct 2014 Interim efficacy and adverse events data from two phase I trials in Acute lymphoblastic leukemia (second-line therapy or greater) released by University of Pennsylvania tisa – gen – lec – leu – cel - T generic name • MesoCART • huCART19 non-proprietary name CRISPR/Cas9
- 8. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score.
- 9. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
- 11. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score.
- 12. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
- 13. CAR-T nomenclature @NascentCAR-TNomenclature Lentiglobin® Lenti-D® Starbeam Study North Star Study branded clinical studies brands
- 15. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
- 17. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score.
- 18. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
- 20. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score.
- 21. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
- 23. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score.
- 24. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
- 26. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score.
- 27. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
- 29. Brand Acumen 19 Leonard St. NY, NY 10013 Bill Smith, CEO (Call Bill. 704.906.3402) william.smith@brandacumenstudios.com